Open Access

Genomic technologies—from tools to therapies

Genome Medicine20179:71

https://doi.org/10.1186/s13073-017-0462-9

Published: 31 July 2017

We are very pleased to invite you to read the first articles in our special issue featuring the development and clinical application of genomic technologies. Our goal was to capture the recent advances in a broad range of technologies used to analyze or manipulate genomic information with the potential to aid in understanding, preventing, diagnosing, and treating disease [1]. The past few years have seen extraordinary developments in areas such as high-throughput sequencing, big-data analysis and storage, genome engineering, and gene therapy. It is now clear that genomic technologies will make a real impact in the clinic, and, although their full potential is still far from being met, areas where transformative applications have been made already include oncology and genetic disease diagnostics.

A particularly active area has been the development of tools for tumor DNA sequencing and analysis. It is now possible to perform high-throughput sequencing of tumor samples and identify the mutations in a patient’s tumor, thus allowing a precise diagnosis and selection of the most appropriate therapy. A common problem in the accurate identification of somatic mutations (genetic changes not present in germline cells) in tumors is the absence of matched normal tissue. To counter this, Lincoln Stein and colleagues have developed ISOWN, software that uses supervised machine learning combined with external databases to identify, with high accuracy, somatic mutations in next-generation sequencing data of tumor samples in the absence of normal samples [2]. ISOWN might be useful in situations where normal tissue was not collected, the patient consent does not allow for its collection, or in retrospective studies.

Another challenging area in tumor sequencing is the identification of genomic rearrangements (gross DNA alterations of chromosomes or large chromosomal regions). Short-read whole-genome sequencing is currently the gold-standard approach, although its accuracy is suboptimal and it is expensive and labor intensive. A proof-of-principle study by Hanlee Ji and colleagues proposes novel methods to resolve genomic rearrangements that drive tumorigenesis using barcode-linked read sequencing of whole genomes [3]. Short-read sequencing is also not an optimal approach to determine trinucleotide repeat counts; this is of paramount importance because trinucleotide-repeat diseases, such as Huntington’s disease, will often manifest only after a certain threshold trinucleotide count, and the number of repeats may influence disease severity. Developments in this area of research have been made by Kai Wang and colleagues [4], where they present RepeatHMM, software that can effectively and efficiently quantify repeat counts from long-read sequencing.

Understanding of Mendelian diseases and complex diseases is also improving, and recently there have been notable advances in neuropsychiatric genomics. Identifying genes involved in these complex disorders should allow a better understanding of disease and improve diagnostics and therapy. Melanie Bahlo and colleagues have developed a web-application, called brain-coX, that focuses on gene prioritization and exploration of gene networks for diseases that originate in human brain tissue in order to identify candidates potentially involved in neurological disorders [5]. Such tools should inevitably draw us closer to mapping the biological basis of psychiatric diseases.

Disease etiology has been linked to microbiome composition, with perhaps the best characterized example so far being the causal link between high levels of Fusobacterim nucleatum in the gut and development of colorectal cancer [6, 7]. In a Comment, Ramnik Xavier and Andrew Tolonen discuss state-of the-art microbial single-cell sequencing technologies and their potential to help characterize the microbiome at the cellular level and understand its role in immunity and disease [8].

Exciting advances are also being observed in genomic technologies to devise better therapies. A valuable tool to identify vulnerabilities in cancer cells that can be targeted for therapy is functional genomic screening with short hairpin RNA (shRNA). However, this field has been plagued by low reproducibility owing to off-target effects. Tero Aittokallio and colleagues perform a systematic comparison of the consistency of two genome-wide shRNA screening datasets and propose a proof-of-principle approach to reduce noise in genome-wide shRNA screens to make them more consistent [9].

Proteogenomics is another approach to uncover druggable targets in cancer that is showing promise as it can identify germline and somatic mutations within crucial cancer genes missed by genomics and transcriptomics. Thomas Kislinger and colleagues perform a systematic investigation of how the choice of database in a proteogenomics study can affect the results and suggest a new strategy to assess the variant peptides identified and their potential impact on cancer biology [10].

The RNA therapeutics field is gaining momentum, with many new therapies reaching clinical trials and the first therapies gaining FDA approval. The main challenges with stability and immunogenicity seem to have been tackled, and delivery and safety are now in the spotlight. In a Review, Daniel Anderson and colleagues discuss recent advances in the delivery of RNA-based therapeutics, such as CRISPR-Cas9 genome-editing technology in research and clinical applications [11].

The large amounts of data generated by the ubiquitous use of sequencing technologies pose challenges to data storage. Cloud computing offers a solution that allows for data to be shared through potential collaboration, but there are regulatory hurdles that must be overcome. In an Opinion article, Jan Korbel and colleagues discuss the regulatory landscape facing cloud computing of patient data for genetics and genomics research both in Europe and in the international context and propose that a federated and hybrid cloud model could be a viable way forward [12].

With the reduction in costs for sequencing technologies expected to continue, more countries will be able to adopt these tools for applications in clinical research and healthcare, with more people able to benefit from data-driven and tailored treatments. Genome Medicine has been at the forefront of communicating advances in the development of genomic technologies with translational potential [13, 14] and demonstrating their clinical application [15]. Looking forward, we are committed to continuing to cover outstanding work in this field and, in particular, the latest in emerging areas.

We hope that you will enjoy this carefully curated collection of articles that showcases some of the most exciting current areas of the genomic technologies field. We will be adding more content over the next few months, so watch this space!

Declarations

Acknowledgements

We thank the Guest Editor, Stephen Kingsmore, for his invaluable guidance planning this special issue and all the authors and reviewers for each of their contributions that allowed it to come to fruition.

Competing interests

AC is an employee of BioMed Central, the publisher of Genome Medicine.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Genome Medicine, BioMed Central

References

  1. Galas DJ, McCormack SJ. An historical perspective on genomic technologies. Curr Issues Mol Biol. 2003;5:123–8.PubMedGoogle Scholar
  2. Kalatskaya I, Trinh QM, Spears M, McPherson JD, Bartlett JMS, Stein L. ISOWN: accurate somatic mutation identification in the absence of normal tissue controls. Genome Med. 2017;9:59.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Greer SU, Nadauld LD, Lau BT, Chen J, Wood-Bouwens C, Ford JM, et al. Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases. Genome Med. 2017;9:57.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Liu Q, Zhang P, Wang D, Gu W, Wang K. Interrogating the “unsequenceable” genomic trinucleotide repeat disorders by long-read sequencing. Genome Med. 2017;9:65.Google Scholar
  5. Freytag S, Burgess R, Oliver KL, Bahlo M. Brain-coX: investigating and visualising gene co-expression in seven human brain transcriptomic datasets. Genome Med. 2017;9:55.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292–8.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299–306.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Tolonen AC, Xavier RJ. Dissecting the human microbiome with single-cell genomics. Genome Med. 2017;9:56.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Jaiswal A, Peddinti G, Akimov Y, Wennerberg K, Kuznetsov S, Tang J, et al. Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells. Genome Med. 2017;9:51.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Kislinger T, Alfaro J, Ignatchenko A, Ignatchenko V, Sinha A, Boutros P. Detecting protein variants by mass-spectrometry: a comprehensive study in cancer cell-lines. Genome Med. 2017;9:62.Google Scholar
  11. Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 2017;9:60.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Molnár-Gábor F, Lueck R, Yakneen S, Korbel JO. Computing patient data in the cloud: practical and legal considerations for genetics and genomics research in Europe and internationally. Genome Med. 2017;9:58.View ArticlePubMedPubMed CentralGoogle Scholar
  13. O'Rawe J, Jiang T, Sun G, Wu Y, Wang W, Hu J, et al. Low concordance of multiple variant-calling pipelines: practical implications for exome and genome sequencing. Genome Med. 2013;5:28.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Inouye M, Dashnow H, Raven L-A, Schultz MB, Pope BJ, Tomita T, et al. SRST2: rapid genomic surveillance for public health and hospital microbiology labs. Genome Med. 2014;6:90.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Miller NA, Farrow EG, Gibson M, Willig LK, Twist G, Yoo B, et al. A 26-hour system of highly sensitive whole genome sequencing for emergency management of genetic diseases. Genome Med. 2015;7:100.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement